Company intelligence / Profile preview
Shandong Jinzhuan Biotechnology
Shandong Sheng, Chinasynapse.patsnap.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Shandong Jinzhuan Biotechnology has developed a UCB-NK cell therapy program for advanced gastric and gastroesophageal cancers. The company sponsored a clinical trial to evaluate safety and preliminary efficacy of this immunotherapy in patients with no effective treatment options. As of January 2025, the highest phase reached is listed as "Pending" and the clinical trial status is unknown; no published results or approvals are available.
- Therapeutic areas
- Oncology
- Modalities
- Cell therapyNK cell therapy (Natural Killer cell therapy)Live biotherapeutic product therapy (as UCB-NK cells are living cells)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Shandong Jinzhuan Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shandong Jinzhuan Biotechnology.